DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,335,320
|Title:||Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies|
|Abstract:||Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed ##STR00001##|
|Inventor(s):||Ebens, Jr.; Allen J. (San Carlos, CA), Friedman; Lori (San Carlos, CA)|
|Assignee:||Genentech, Inc. (South San Francisco, CA)|
|Patent Claims:||1. A method for selecting compounds to be used in combination for the treatment of an hematopoietic malignancy comprising: a) administering synergistic effective amounts of a
therapeutic combination of a compound selected from Formula Ia: ##STR00056## and a chemotherapeutic agent selected from dexamethasone, thioTEPA, doxorubicin, vincristine, rituximab, cyclophosphamide, prednisone, melphalan, lenalidomide, bortezomib,
rapamycin, and cytarabine to tumor cells; b) measuring a decrease in p-Akt levels; and c) selecting a synergistic therapeutic combination for the treatment of the hematopoietic malignancy which shows a decrease in p-Akt levels.
2. The method of claim 1 wherein the decrease in p-Akt level is determined by reduction of p-AKT, p-S6RP, p-Bad, or beta-actin.
3. The method of claim 1 wherein the hematopoietic malignancy is selected from non-Hodgkin's lymphoma, diffuse large hematopoietic lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma, acute myeloid leukemia (AML), and myeloid cell leukemia (MCL).
4. The method of claim 1 wherein the chemotherapeutic agent is rituximab.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||RITUXAN||rituximab||VIAL||103705||001||1997-11-26||See Pricing||Genentech, Inc. (South San Francisco, CA)||2036-05-13||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2010105008||Nov 25, 2010|
|World Intellectual Property Organization (WIPO)||2010105008||Sep 16, 2010|
|United States of America||2010233164||Sep 16, 2010|
|United States of America||2013330765||Dec 12, 2013|
|United States of America||8536161||Sep 17, 2013|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.